The AJMC® Migraine compendium is a comprehensive resource for clinical news and expert insights for the recurring type of headache, which is accompanied by side effects.
November 18th 2025
Based on this analysis, all 3 gepants are not cost-effective compared with usual care for the treatment of acute migraine.
February 3rd 2025
Dr Peter McAllister on How COVID-19 Has Impacted Migraine Prevention Efforts
October 22nd 2020Increased time spent in front of computer screens, less time spent sleeping, and less access to gyms have led my patients to have a lot more migraines, said Peter McAllister, MD, a neurologist, board certified headache specialist, and medical director of the New England Institute for Neurology and Headache.
Watch
Dr Messoud Ashina Talks Through the 5-Year Safety and Efficacy Data on Erenumab
October 19th 2020Data from a 5-year open-label treatment period on the safety profile of erenumab (Aimovig) showed the treatment helped patients with episodic migraine achieve a sustained reduction in the number of monthly migraine days and the number of days in which therapies were needed for acute migraines.
Read More
Dr Rigmor Jensen Discusses Prevalence of Medication Overuse Headache
October 13th 2020Medication overuse headache is a huge problem in societies that don't have access to proper headache care as patients take more over-the-counter, readily available treatments, said Rigmor Jensen, MD, professor of neurology at The University of Copenhagen and director of the Danish Headache Center.
Watch
Smartphone App Unable to Accurately Predict Episodic Migraine
October 7th 2020In an attempt to develop a multivariable predictive model for days with new-onset migraine headaches, researchers found episodic migraine attacks were not predictable based on self-prediction or on self-reported exposure to common trigger factors.
Read More
Study Finds GONB With Bupivacaine Inferior to IV Metoclopramide as First-line Treatment for Migraine
September 30th 2020According to a study published in Headache, greater occipital nerve blocks (GONB) with bupivacaine were not as effective as intravenous (IV) metoclopramide as a first-line treatment for migraineurs who presented to emergency departments.
Read More
Green Light Exposure Therapy May Reduce Migraine Frequency
September 17th 2020In individuals suffering from chronic and episodic migraine, a preliminary study shows exposure to green light therapy significantly reduced headache days and improved both intensity and duration of headache attacks.
Read More
Study Analyzes Effects of Erenumab Based on MMD Reduction Threshold
August 31st 2020Using data from the Study to Evaluate the Efficacy and Safety of Erenumab in Migraine Prevention, researchers were able to analyze the efficacy of erenumab at ≥50%, ≥75%, and 100% thresholds for reduction in monthly migraine days.
Read More
How Do Headache-Free Days Impact Migraine-Related Disability?
August 17th 2020A higher number of headache-free days (HFDs) is associated with decreased headache-related disability among individuals with migraine, according to a study published in the Journal of Managed Care & Specialty Pharmacy.
Read More
Real-Word Evidence Outlines Efficacy of Erenumab for Highly Therapy-Refractory Migraine
August 5th 2020A study based on real-world data collected from the West German Headache Center at the University Hospital Essen, Germany, concluded erenumab appears to be a promising treatment option for patients with highly therapy-refractory migraine.
Read More
Erenumab Autoinjector Well Received by Patients, Study Finds
July 28th 2020When it comes to ease of use, ability to self-inject, and confidence in using an erenumab-prefilled disposable autoinjector, individuals with migraine consistently endorsed the preventive treatment, according to study results published in Patient Preference and Adherence.
Read More
Data Highlight Long-Term Efficacy of Erenumab for Episodic Migraine
July 28th 2020In patients with episodic migraine, erenumab provided sustained efficacy for the condition over the course of 1 year, according to new results from a study to evaluate the efficacy and safety of erenumab in migraine prevention (STRIVE), published in Neurology.
Read More
Review Explores Association Between Chronic Migraine, Suicide Ideation
July 23rd 2020Current existing research highlights the important association between the increased risk of suicidal behaviors among chronic migraineurs with and without aura, in both the clinical and general population worldwide, according to a systematic review published in Frontiers in Neurology.
Read More
Meta-Analysis Outlines Interrelationship of Migraine, Blood Pressure
July 22nd 2020Positive genetic correlations of migraine with diastolic blood pressure (BP) and systolic BP exist, supporting the notions that diastolic BP plays a critical role in migraine susceptibility and BP and migraine share underlying biological mechanisms, according to a study published in Nature Communications.
Read More
Can Adulthood Attachment Mediate the Effects of Childhood Trauma on Migraine?
July 16th 2020The direct effect of childhood trauma on migraine is outweighed by the mediation effect of adulthood attachment, according to a study published in the International Journal of Environmental Research and Public Health.
Read More
Can Machine Learning Predict Medication Overuse in Migraineurs?
July 15th 2020A combination of machine learning and random optimization may aid in predicting medication overuse in migraineurs, if clinical/biochemical features, drug exposure, and lifestyle are taken into consideration, according to a study published in Computational and Structural Biotechnology Journal.
Read More
How Does Quarantine Impact Migraineurs?
July 7th 2020A survey conducted among migraineurs in Genova, Italy, found that during the coronavirus disease 2019 (COVID-19) quarantine, patients experienced fewer migraine attacks and less pain but exhibited moderate levels of depression correlated to migraine burden.
Read More